Patients with a high P/C ratio for CD44 had significantly earlier tumor progression and a worse outcome than those with a low P/C ratio for CD44 (PFS: 9 ± 4.24 months (high P/C ratio) versus not available (NA) (low P/C ratio), p = 0.0359; OS: 16 ± 3.78 months (high P/C ratio) versus 26 ± 5.22 months (low P/C ratio), p = 0.0215). The gene discussed is CD44; the disease is neoplasm.